Bayer (FRA:BAYN)‘s stock had its “buy” rating reiterated by research analysts at DZ Bank in a research note issued to investors on Thursday, Borsen Zeitung reports.
Other analysts also recently issued reports about the company. Kepler Capital Markets set a €73.00 ($84.88) price objective on Bayer and gave the company a “neutral” rating in a report on Thursday, January 9th. Sanford C. Bernstein set a €90.00 ($104.65) price objective on Bayer and gave the company a “buy” rating in a report on Monday. JPMorgan Chase & Co. set a €75.00 ($87.21) price objective on Bayer and gave the company a “neutral” rating in a report on Monday, January 6th. Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the company a “buy” rating in a report on Thursday, December 5th. Finally, Nord/LB set a €64.00 ($74.42) price objective on Bayer and gave the company a “neutral” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the stock. Bayer has an average rating of “Buy” and a consensus price target of €79.94 ($92.95).
FRA BAYN traded down €0.49 ($0.57) on Thursday, reaching €74.83 ($87.01). The company had a trading volume of 1,216,348 shares. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98). The business has a 50 day moving average of €71.61 and a two-hundred day moving average of €66.01.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: What does the Dogs of the Dow mean?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.